Skip to content

Comparison of IVF/ICSI efficacy of different progestins in patients with polycystic ovary syndrome

Comparison of IVF/ICSI efficacy of different progestins in patients with polycystic ovary syndrome

Status
Recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR1800016284
Enrollment
Unknown
Registered
2018-05-24
Start date
2018-05-22
Completion date
Unknown
Last updated
2018-05-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

polycystic ovary syndrome

Interventions

test group:hMG + dydrogesterone
control group:hMG + MPA

Sponsors

Shanghai First Maternity and Infant Hospital, Tongji University School of Medicine, Shanghai, China
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
18 Years to 37 Years

Inclusion criteria

Inclusion criteria: 1. First peroid of IVF/ICSI; 2. Aged < 38 years old; 3. Meet the diagnostic criteria for polycystic ovary syndrome.

Exclusion criteria

Exclusion criteria: 1. Systemic disease; 2. Patients with endometriosis grade III or higher; 3. Patients with premature ovarian failure; Hyperprolactinemia, ovarian neoplasms; Uterine malformations (dual uterus, mediastinal uterus, etc.); History of recurrent miscarriage (3 or more spontaneous abortions); 4. Patients with acute and chronic genital tract tumors, genital tract inflammation, and other diseases that are not suitable for ovulation; 5. Patients taking steroids within the last 3 months.

Design outcomes

Primary

MeasureTime frame
FSH;FSH;LH;E2;Estradiol;Progesterone;Gn dosage;Medication days;Obtained eggs;Number of mature eggs;High quality embryo number;

Secondary

MeasureTime frame
Other embryonic laboratory results;

Countries

China

Contacts

Public ContactAI AI

Shanghai First Maternity and Infant Hospital, Tongji University School of Medicine

aiai6905@163.com+86 13661991114

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026